Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and newly diagnosed with advanced stage 3 or 4 ovarian, fallopian tube, or primary peritoneal cancer.
- You must have a BRCA1 or BRCA2 gene mutation confirmed by genetic testing.
- Your cancer must be the high-grade serous type or a similar aggressive type, and it cannot be fully removed with surgery at this time.
- You must have at least one tumor that can be seen on a CT or MRI scan.
- You must be in generally good health with adequate organ function (kidneys, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.